{"entity":{"type":"insider","cik":"0001651537","url":"/insider/0001651537","json_url":"/insider/0001651537.json","name":"Erlander Mark","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":4,"n_filings":4,"first":"2016-12-15","last":"2022-11-29","span_basis":"filed_date"},"name_variants":[{"name":"Erlander Mark","source":"filing","n_filings":4,"first_seen":"2016-12-15","last_seen":"2022-11-29"}],"transactions":[{"id":6792597,"accession":"0001628280-22-030946","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-22-030946","line_url":"/filing/0001628280-22-030946#line-1","is_derivative":false,"issuer_cik":"0001213037","issuer_name":"Cardiff Oncology, Inc.","issuer_ticker":"CRDF","issuer_name_source":null,"issuer_url":"/issuer/0001213037","owner_cik":"0001651537","owner_name":"Erlander Mark","owner_url":"/insider/0001651537","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":1.43,"price_display":"1.43","price_state":"stated","total_value":14300.0,"total_display":"14,300.00","shares_owned_after":24481.0,"shares_owned_after_display":"24,481","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-25","filed_date":"2022-11-29","scope":"insider"},{"id":5166869,"accession":"0001628280-21-005335","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-21-005335","line_url":"/filing/0001628280-21-005335#line-1","is_derivative":false,"issuer_cik":"0001213037","issuer_name":"Cardiff Oncology, Inc.","issuer_ticker":"CRDF","issuer_name_source":null,"issuer_url":"/issuer/0001213037","owner_cik":"0001651537","owner_name":"Erlander Mark","owner_url":"/insider/0001651537","role":"Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":965.0,"shares_display":"965","price_per_share":10.3417,"price_display":"10.34","price_state":"stated","total_value":9979.7405,"total_display":"9,979.74","shares_owned_after":14481.0,"shares_owned_after_display":"14,481","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-23","filed_date":"2021-03-23","scope":"insider"},{"id":2921929,"accession":"0001104659-20-063184","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-063184","line_url":"/filing/0001104659-20-063184#line-1","is_derivative":false,"issuer_cik":"0001213037","issuer_name":"Cardiff Oncology, Inc.","issuer_ticker":"CRDF","issuer_name_source":null,"issuer_url":"/issuer/0001213037","owner_cik":"0001651537","owner_name":"Erlander Mark","owner_url":"/insider/0001651537","role":"Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6993.0,"shares_display":"6,993","price_per_share":1.43,"price_display":"1.43","price_state":"stated","total_value":9999.99,"total_display":"9,999.99","shares_owned_after":13369.0,"shares_owned_after_display":"13,369","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-14","filed_date":"2020-05-18","scope":"insider"},{"id":2824299,"accession":"0001104659-16-162330","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-16-162330","line_url":"/filing/0001104659-16-162330#line-1","is_derivative":false,"issuer_cik":"0001213037","issuer_name":"Trovagene, Inc.","issuer_ticker":"TROV","issuer_name_source":null,"issuer_url":"/issuer/0001213037","owner_cik":"0001651537","owner_name":"Erlander Mark","owner_url":"/insider/0001651537","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.075,"price_display":"2.08","price_state":"stated","total_value":10375.0,"total_display":"10,375.00","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-12-14","filed_date":"2016-12-15","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":4,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":4},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001213037","name":"Cardiff Oncology, Inc.","url":"/issuer/0001213037","role":"Director, Officer (Chief Executive Officer)","n_filings":4,"first_seen":"2016-12-15","last_seen":"2022-11-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001651537","retrieved_at":"2026-08-20T17:05:23+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-19","last_ingest":"2026-08-20T05:22:56.381658+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}